Industry and regulators need to collaborate to provide complex generics with the opportunity to build even further on the significant contributions already made by off-patent medicines to savings and access, Christine Baeder, senior vice president and chief operating officer of Teva’s US generics division, tells Generics Bulletin in the first part of an exclusive interview.
When Teva published its economic impact report for 2020 earlier this year, the numbers were a reminder of the significant impact that generic medicines have on healthcare systems worldwide.
Across 14 countries, the company said it had contributed savings to healthcare systems of $43.1bn in 2020. Of this total,...